Carbamazepine, compliant with the standards set by Indian Pharmacopoeia (IP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and United States Pharmacopeia (USP), is a widely used anticonvulsant and mood-stabilizing medication. It is indicated for the treatment of epilepsy, bipolar disorder, and trigeminal neuralgia. Carbamazepine operates primarily by inhibiting voltage-gated sodium channels, thus reducing neuronal excitability. Its efficacy in managing seizures and mood disorders has made it a cornerstone therapy in neurological and psychiatric care. Ensuring adherence to pharmacopoeial specifications guarantees the quality, potency, and safety of Carbamazepine formulations, reinforcing its role as a trusted medication in clinical practice.